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Catheter-related Candidemia Caused by Candida haemulonii 
in a Patient in Long-term Hospital Care
Candida haemulonii, one of the non-albicans Candida species, is an emerging yeast 
pathogen that is known to be resistant to amphotericin B and other antifungal agents such 
as azoles. These anti-fungal agents have often been associated with clinical treatment 
failure, so no treatment regimen has been clearly established for invasive C. haemulonii 
infections. We investigated a catheter-related infection of C. haemulonii candidemia in an 
adult patient in long-term hospital care. In the early stages, the candidemia remained 
persistent despite treatment with fluconazole. However, after changing the antifungal 
agent to caspofungin, the candidemia was resolved. Fluconazole and amphotericin B are 
not reliable empirical antifungal agents for invasive C. haemulonii infections, as shown in 
previous case reports. An echinocandin such as caspofungin may be an appropriate 
empirical choice of antifungal agent for an invasive C. haemulonii infection.
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INTRODUCTION
The proportion of candidemia cases caused by non-albicans 
Candida species has been increasing (1). Some non-albicans 
Candida species are associated with resistance to the usual an-
tifungal azoles (2). C. haemulonii, a non-albicans Candida spe-
cies, does not frequently cause human infections (3). Microbio-
logically, the susceptibility profile of C. haemulonii shows that it 
is resistant to amphotericin B and other antifungal agents such 
as azoles (4), which have often been associated with clinical treat-
ment failure (5, 6). No treatment regimen for invasive C. haem-
ulonii infections has been clearly established.
  We investigated a catheter-related candidemia infection due 
to C. haemulonii and report on resolution of the infection using 
caspofungin, an echinocandin antifungal agent.
CASE DESCRIPTION
On June 25, 2009, a 67-yr-old man with a cerebral infarction was 
hospitalized in the department of rehabilitation medicine for 
physical rehabilitation. Prior to admission, he experienced cere-
bral infarction and was hospitalized for two months, beginning 
in March, 2009. He had received a tracheostomy at his previous 
admission. 
  A physical examination did not reveal any signs of infection, 
including at the tracheostomy site. The patient received a right 
subclavian venous catheter for total parenteral nutrition on the 
second day of hospitalization because of the risk of aspiration 
when receiving nasogastric tube feedings.
  On August 15 (the 50th day of hospitalization), the patient 
had a temperature of 37.8°C, a white cell count of 10.4 × 10
9/li-
ter, and a C-reactive protein level of 10.8 mg/liter. However, the 
blood culture failed to reveal any infectious organism. The mild 
fever continued, and the level of CRP and white cell count con-
tinued to increase. 
  On August 29 (the 64th day of hospitalization), a blood cul-
ture collected 72 hr previously showed yeast growth, and the 
subclavian venous catheter was removed. Intravenous flucon-
azole (400 mg once a day) was administered as empirical thera-
py, pending identification of the yeast. A qualitative culture of 
the catheter tip also produced a yeast culture. 
  The yeast from the blood culture and catheter tip, designated 
as LYS-1, was identified as Candida sp. on the seventh day of 
fluconazole therapy. The physician continued the fluconazole 
therapy for the candidemia. The blood cultures performed on 
the fourth and 14th days of fluconazole therapy were still posi-Kim S, et al.  •  Catheter Related Candidemia by Candida haemulonii
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tive for yeast, and the mild fever persisted.
  On September 15 (the 18th day of fluconazole treatment), 
the infectious disease department was consulted and recom-
mended an echocardiography, a bone scan, an abdominal CT, 
and Doppler sonography for venous thrombosis. The echocar-
diograph revealed no signs of infectious endocarditis. The bone 
scan, abdominal CT, and Doppler sonography revealed no sig-
nificant findings. 
  On September 17 (the 84th day of hospitalization), the treat-
ment regimen was changed to caspofungin (50 mg daily after a 
70 mg loading dose). The blood culture was sterile on the third 
and tenth days of caspofungin therapy. On the second day of the 
caspofungin treatment, the patient became afebrile and showed 
clinical improvement. In resolution, the patient underwent a 
17-day course of caspofungin and remained stable after discon-
tinuation of the antifungal agent.
Molecular identification
Conventional automated methods in the clinical microbiology 
laboratory identified the LSY-1 isolate as Candida sp. Thus, we 
attempted to identify the culture at the species level using a mo-
lecular method. To identify the isolate LSY-1, a portion of the 
large subunit (LSU) rRNA gene was amplified using the prim-
ers LSU-F (5´-GCATATCAATAAGCGGAGGAAAAG-3´) and LSU-
R (5´-GGTCCGTGTTTCAAGACG-3´). Template DNA and 20 
pM of each primer were added to a PCR mixture tube (Accu-
Power PCR PreMix; Bioneer, Daejeon, Korea). The reaction mix-
ture was then subjected to 35 cycles of amplification. Each cycle 
consisted of 30 sec at 95°C, 30 sec at 50°C, and 1 min at 72°C, fol-
lowed by a final extension at 72°C for 1 min. The amplified PCR 
product was purified for sequencing using a PCR purification 
kit. The purified PCR product was sequenced directly using the 
same primers as those used in the PCR amplification. The de-
termined sequences (519 bp) were compared with the Gen-
Bank public database using the BLASTn program (http://blast.
ncbi.nlm.nih. gov/Blast.cgi). The LSU rRNA gene sequence of 
the isolate LSY-1 was a complete match with the corresponding 
sequence of the reference strain, C. haemulonii strain TJY2d 
(GenBank accession numbers EU359820). In addition, the iso-
late in question showed many similarities to the sequences of 
the C. haemulonii strains and similarities of less than 85% with 
Table 1. Clinical characteristics of patients with C. haemulonii candidemia, and the antifungal susceptibility data of C. haemulonii isolates
Year of 
report
Author
Patient  
no.
Age/sex
Underlying 
characteristic
Cause of 
candidemia
Initial 
anti-
fungal 
agent
Initial 
out-
come
Seondary 
anti-
fungal 
agent
Final 
out-
come
MIC (mg/L)
AMB FLC ITC VCZ CAS MFG
2002 Rodero et al. Patient 1 83 yr/M Megaloblastic 
anemia
Catheter related 
infection
None Success None Success  4 32 0.12 NA NA NA
2006 Giusiano et al. Patient 2 NA NA Catheter related 
infection
NA NA NA NA 1 32 NA NA NA NA
2007 Khan et al. Patient 3 35  
week/M
Neonate Catheter related 
infection
AMB Failure AMB
CAS
 
Failure
 
4
 
96
 
2
 
0.047
 
0.5
 
NA
Patient 4 26  
week/M
Neonate Catheter related 
infection
FLC Success none Success 6 > 256 3 0.125 0.5 NA
Patient 5 25  
week/F
Neonate Catheter related 
infection
AMB Failure AMB CAS Success 2 > 256 2 0.125 0.023 NA
Patient 6 31  
week/F
Neonate Catheter related 
infection
AMB Failure none Failure 4 > 256 4 0.125 0.125 NA
2009 Kim et al. Patient 7 10 yr/M Nasopharyngeal 
cancer
Catheter related 
infection
ITC Failure AMB Failure 1 64 4 1 0.125 0.06
2010 Ruan et al. Patient 8 85 yr/M Rectal cancer Intra-abdominal 
infection
FLC Failure MFG Success 2 16 0.25 0.25 1 0.12
Patient 9 79 yr/M Pneumonia Catheter related 
infection
FLC Success none Success 2 16 0.25 0.25 1 0.12
2010
(our case)
Kim et al. Patient 10 67 yr/M Neurologic 
disability
Catheter related 
infection
FLC Failure CAS Success 0.5 8 0.25 0.5 0.125 NA
MIC, minimum inhibitory concentration; AMB, amphotericin B; FLC, fluconazole; ITC, itraconazole; VCZ, voriconazole; CAS, caspofungin; MFG, micafungin; NA, not available.
C. pseudohaemuloniiC4511
Noctiluca scintillans GSW0205
C. pseudohaemuloniiC4370
C. pseudohaemuloniiC4368
C. pseudohaemuloniiC4369
C. chanthaburiensisEM33Q
Candidasp. AS2-3483
Clavispora reshetovae HEG-9-2
Candidasp. JHS-2008 C4416
Candidasp. JHS-2008 C4510
Candidasp. JHS-2008 C4339
LYS-1
C. haemuloniiTJY2b
C. haemuloniiC4512
C. haemuloniiTJY2d
C. haemuloniiTJY2a
C. haemuloniiKw153-05
C. haemuloniiKw153-06
Candidasp. NRRL Y-27702
C. ruelliae MTCC 7739
Fig. 1. Phylogenetic tree analysis of a large subunit (LSU) rRNA gene of isolated 
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other Candida species (Fig. 1). Thus, the sample was confident-
ly identified as C. haemulonii. 
DISCUSSION
C. haemulonii was originally described from a sample taken 
from the gut of a blue-striped grunt (Haemulon scirus) in 1962 
(7), and Lavarde et al. (8) reported the first clinical isolation of 
this fungus from a human in 1984.
  Several meaningful cases of C. haemulonii candidemia have 
been reported (Table 1). Antifungal resistance is the focus of at-
tention in the management of invasive candidiasis. In previous 
cases, most C. haemulonii were resistant to both fluconazole and 
amphotericin B (5, 9). Clinically, when amphotericin B was ad-
ministered empirically, it failed to eradicate C. haemulonii can-
didemia (5). The majority of cases in which fluconazole was ad-
ministered empirically also failed to eradicate candidemia (5, 6). 
Although fluconazole administration has been shown to resolve 
candidemia, these cases could be considered transient candi-
demia combined with the removal of the intravenous catheter. 
Therefore, the resistance of C. haemulonii poses a therapeutic 
challenge for the treatment of invasive candidiasis. 
  Microbiologically, previous reports and our case show that C. 
haemulonii is susceptible to echinocandins such as caspofun-
gin or micafungin (5, 6, 10), and that it was not resistant to new 
triazoles such as voriconazole. However, it is not certain that 
echinocandins or voriconazole are actually efficacious in the 
treatment of C. haemulonii candidemia. There have been only 
two cases of clinical success in the eradication of C. haemulonii 
candidemia via echinocandins administration (5, 6). One case 
used micafungin, and the other used caspofungin. Of those, in 
the treatment with caspofungin of a neonate, echinocandin was 
combined with amphotericin B. Therefore, our case could dem-
onstrate clinical success with caspofungin administration in the 
eradication of C. haemulonii candidemia in an adult patient. 
  In our case, the VITEK II (bioMérieux SA) clinical yeast iden-
tification system was used for initial identification of C. haemu-
lonii, and sequence analysis of the partial 26s rRNA gene (519 bp) 
was performed for confirmation. The 519-bp sequences of the 
isolate matched completely with the corresponding sequen  ces 
of the reference strain, C. haemulonii strain TJY2d, available in 
the GenBank database (accession number EU359820). In recent 
studies, the identification results of the VITEK 2 system have 
closely corresponded with those of molecular methods for the 
identification of C. haemulonii, while the VITEK 1 system and 
the API 32C system usually fail to identify C. haemulonii (5, 10).
  Known risk factors for candidemia are use of central-venous 
catheterization, total parenteral nutrition, previous multiple an-
tibiotics, previous steroid therapy, previous abdominal surgery, 
and an immunocompromised status (11, 12).
  In our case, long-term central-venous catheterization for hy-
peralimentation was the associated risk factor for candidemia, 
and no other source of infection suggested the possibility of cath-
eter-related candidemia. In previous case reports, the majority 
of patients also received an intravenous central line and were in 
an immunocompromised status.
  Considering the recent case series of invasive C. haemulonii 
infections, C. haemulonii is considered to be an emerging yeast 
pathogen for which the optimal strategy of patient management 
has yet to be elucidated.
  In conclusion, as found in the previous case reports, flucon-
azole and amphotericin B are not reliable empirical antifungal 
agents for the treatment of C. haemulonii candidemia. Echino-
candins, such as caspofungin or micafungin, may be an appro-
priate empirical choice of antifungal agent for invasive C. hae-
mulonii infections. New triazoles require additional clinical test-
ing for treatment of C. haemulonii infection.
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